Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028367 | 0.93 | SIGMAR1 (0.41) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL10225216 | 0.91 | SIGMAR1 (0.44) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL22837700 | 0.91 | SIGMAR1 (0.44) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL15535769 | 0.91 | SIGMAR1 (0.44) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL24673520 | 0.91 | SIGMAR1 (0.44) | SIGMAR1LMNAKDM5AKDM4CGGPS1 | |
| SCHEMBL9945708 | 0.90 | GGPS1 (0.38) | LMNAKDM5AKDM4CGGPS1CHRM2 | |
| SCHEMBL4122365 | 0.89 | LMNA (0.43) | SIGMAR1LMNAKDM4CGGPS1CHRM2 | |
| SCHEMBL17831487 | 0.88 | GGPS1 (0.46) | KDM5AKDM4CGGPS1CHRM2S1PR2 | |
| SCHEMBL29580790 | 0.87 | LMNA (0.41) | SIGMAR1LMNAKDM4CCHRM2PIK3CD | |
| SCHEMBL29580455 | 0.87 | LMNA (0.41) | SIGMAR1LMNAKDM4CCHRM2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-3816164-B9 | ISOTHIAZOLO[5,4-D]PYRIMIDINE COMPOUND AS IRAK4 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2024-07-10 | — | — | EP | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| EP-3894410-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-10-11 | — | — | EP | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200140831-A1 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | THE JOHNS HOPKINS UNIVERSITY | 2020-05-07 | — | — | US | disclosed |
| US-10638759-B2 | Conjugated polyelectrolytes and methods of using the same | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190308907-A1 | COATED-FINE-AGGREGATE, CONCRETE COMPOSITION AND METHOD | AQUASMART ENTPR LLC (US) | 2019-10-10 | — | — | US | disclosed |
| US-9982009-B2 | Methods for treating polycystic kidney disease and polycystic liver disease | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180020663-A1 | CONJUGATED POLYELECTROLYTES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2018-01-25 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-2323980-B1 | 7-(PIPERAZINE-1-YMETHYL)-1H-INDOLE-2-CARBOXYLIC ACID (PHENYL)-AMIDE DERIVATIVES AND ALLIED COMPOUNDS AS P38 MAP KINASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2012-02-29 | — | — | EP | disclosed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | SIGMAR1 4258/4885LMNA 1955/4885KDM5A 4713/4885 |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | SIGMAR1 2878/4885LMNA 4560/4885KDM5A 536/4885 |
| US-10638759-B2 | Conjugated polyelectrolytes and methods of using the same | PARN, TERB1, CDYL | SIGMAR1 922/4885LMNA 1037/4885KDM5A 512/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885LMNA 1656/4885KDM5A 197/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | SIGMAR1 3022/4885LMNA 321/4885KDM5A 55/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885LMNA 1656/4885KDM5A 197/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885LMNA 1656/4885KDM5A 197/4885 |
| US-11697804-B2 | Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy | POLRMT, HDGF, PCNP | SIGMAR1 1370/4885LMNA 2375/4885KDM5A 3801/4885 |
| US-20180020663-A1 | CONJUGATED POLYELECTROLYTES AND METHODS OF USING THE SAME | PARN, TERB1, CDYL | SIGMAR1 1063/4885LMNA 998/4885KDM5A 502/4885 |
| US-20200140831-A1 | TRANSCRIPTIONALLY TARGETED AND CPG-FREE PLASMID FOR THERANOSTIC GENE THERAPY | POLRMT, HDGF, PCNP | SIGMAR1 1370/4885LMNA 2375/4885KDM5A 3801/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | SIGMAR1 764/4885LMNA 3018/4885KDM5A 3470/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SIGMAR1 3199/4885LMNA 1656/4885KDM5A 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.